Market Access

Patient Assistance Programs (PAPs) came out of the shadows in 2020 as several factors aligned that increased demand and awareness of these programs.

Taking a closer look at the evolving legal treatment of coupons and copay accumulators.

Outlining the steps to a payment approach for Medicare Part D drugs that provides savings for patients.

2020 has proven to be a year like no other for pharma. Here is a quick look back at some of the trends 2020 created for the industry.

If telehealth is here to stay, how is the industry adjusting?

How technology can maximize use of manufacturer copay and patient assistance programs.

The importance of life sciences companies focused on rare diseases to take early steps to bridge connections with patients, caregivers, and healthcare providers.

A check on the evolving challenges and potential solutions in steering future market adoption of curative-intended treatments.

Following a year which saw a 143% increase in launched biosimilars in the US, here are three reasons why payers will drive adoption further in 2021.

Following the announcement of his new role, Pharm Exec had the chance to speak with Daniel Schroen, PhD about his past experience as well as the landscape of the therapeutic development industry.

Therapeutic companies that work with rare diseases must take early steps to build relationships with patients, caregivers, and HCPs.

A look at best-practice approaches to aligning the strategy and design of hub service models with preparations for market entry of a new therapy.

While gene therapies continue to revolutionize healthcare, uncertainty from commercialization issues still looms large.

Amid pandemic, rely on the fundamentals.

Looking at four building blocks of success, Wolfram Lux and Simone Seiter investigate what it takes to win and be successful when commercializing an orphan drug

A look into the complex battle between pharmaceutical manufacturers and payers for balance between medication access and budget management.

Knowing that product reimbursement affects performance and varies by geography, this article proposes the use of Reimbursement Benchmark Share (RBS) to quantify the influence of reimbursement on a product’s performance.

With new access levers emerging, positioning products will require a shift form the traditional launch playbook.

Proposals around the globe seek to ensure access to any promising treatments.

Examining the key learnings from BCG’s 2019 benchmark study-and the capabilities uncovered that will be critical to future performance.

Banks Bourne of Tanner Pharma Group talks about the organization's role in delivering access initiatives for products not commercially available in many parts of the world.

Three product launch trends driven by emerging biopharma.

Renewed education efforts by employers, however, are slowly helping them take back decision-making reins in their engagements with pharma.

Lundbeck executive Taj Bhardwaj talks about the differing mindsets necessary to lead local and global-level market access strategy in pharma-and how his current company is committed to stay in the fight to advance new treatments and break down stigmas in mental health.

Exploring the roadmap for US-based, R&D-focused biopharma companies seeking to successfully penetrate product markets and reach patients in Europe.